首页 > 最新文献

Breast disease最新文献

英文 中文
Quality of life assessment of breast cancer survivors in Northern Morocco: Rural-urban disparity. 摩洛哥北部癌症乳腺癌幸存者的生活质量评估:鲁城差异。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230012
Fadoua El Battioui, Fatima El Malki, Said Barrijal

This article is a cross-sectional study of 216 women undergoing adjuvant hormone therapy for breast cancer in two oncology centers in northern Morocco. Quality of life (QoL) was assessed using the Functional Assessment of Cancer Therapy (FACT) questionnaire and its endocrine subscale (ES). The relationship between rural-urban status in our sample and QoL was assessed by linear regression analysis using sociodemographic and clinical variables as covariates. Our results show that physical and functional well-being are significantly (p < 0.001) higher in rural areas (24 and 29, respectively) than in urban areas (16 and 19, respectively), while social and emotional well-being are significantly (p < 0.001) higher in urban areas (22 and 21, respectively) than in rural areas (15 and 16, respectively). However, there was no significant difference (p = 0.097) between rural and urban breast cancer survivors regarding endocrine symptom burden. Regarding the effect of sociodemographic and clinical factors on overall HRQOL of breast cancer survivors, hormone type was shown to have a significant effect on overall HRQOL (FACT-ES) of rural and urban breast cancer survivors (𝛽 = +0.849 and 𝛽 = +0.678, respectively). A similar effect was observed for ES (𝛽 = +0.896 and 𝛽 = +0.180, respectively).In contrast, other factors (age, marital status, economic status, menopausal status, type of surgery) did not have a significant effect on HRQOL (FACT-ES) or ES.The study highlighted the need for increased psychosocial supportive care efforts for rural breast cancer survivors to improve their QoL.

本文是对摩洛哥北部两个肿瘤中心216名接受辅助激素治疗的女性癌症的横断面研究。使用癌症治疗功能评估(FACT)问卷及其内分泌分量表(ES)评估生活质量(QoL)。使用社会人口统计学和临床变量作为协变量,通过线性回归分析评估了我们样本中的城乡状况与生活质量之间的关系。我们的研究结果表明,身体和功能的幸福感显著(p
{"title":"Quality of life assessment of breast cancer survivors in Northern Morocco: Rural-urban disparity.","authors":"Fadoua El Battioui,&nbsp;Fatima El Malki,&nbsp;Said Barrijal","doi":"10.3233/BD-230012","DOIUrl":"https://doi.org/10.3233/BD-230012","url":null,"abstract":"<p><p>This article is a cross-sectional study of 216 women undergoing adjuvant hormone therapy for breast cancer in two oncology centers in northern Morocco. Quality of life (QoL) was assessed using the Functional Assessment of Cancer Therapy (FACT) questionnaire and its endocrine subscale (ES). The relationship between rural-urban status in our sample and QoL was assessed by linear regression analysis using sociodemographic and clinical variables as covariates. Our results show that physical and functional well-being are significantly (p < 0.001) higher in rural areas (24 and 29, respectively) than in urban areas (16 and 19, respectively), while social and emotional well-being are significantly (p < 0.001) higher in urban areas (22 and 21, respectively) than in rural areas (15 and 16, respectively). However, there was no significant difference (p = 0.097) between rural and urban breast cancer survivors regarding endocrine symptom burden. Regarding the effect of sociodemographic and clinical factors on overall HRQOL of breast cancer survivors, hormone type was shown to have a significant effect on overall HRQOL (FACT-ES) of rural and urban breast cancer survivors (𝛽 = +0.849 and 𝛽 = +0.678, respectively). A similar effect was observed for ES (𝛽 = +0.896 and 𝛽 = +0.180, respectively).In contrast, other factors (age, marital status, economic status, menopausal status, type of surgery) did not have a significant effect on HRQOL (FACT-ES) or ES.The study highlighted the need for increased psychosocial supportive care efforts for rural breast cancer survivors to improve their QoL.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"291-298"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41102381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The epidemiological and clinicopathological characteristics of multifocal/multicentric breast cancer in the Egyptian Delta and its impact on management strategies. 埃及三角洲多灶/多中心乳腺癌的流行病学和临床病理特征及其对管理策略的影响
Pub Date : 2023-01-01 DOI: 10.3233/BD-220066
Ahmed Abdallah, Omar Hamdy, Mohammad Zuhdy, Saleh S Elbalka, Mohamed Abdelkhalek, Amir M Zaid, Ahmed Atef, Mohamed G Elmadawy, Basel Refky, Khaled Abdel Wahab, Dalia Bayoumi, Khadiga M Ali, Islam H Metwally, Mosab Shetiwy

Background: Multifocal (MFBC)/multicentric (MCBC) breast cancer is being more recognized due to the improved imaging modalities and the greater orientation with this form of breast cancer, however, optimal surgical treatment, still poses a challenge. The standard surgical treatment is mastectomy, however, breast-conserving surgeries (BCS) may be appropriate in certain situations.

Methods: A total of 464 cases of MF/MCBC out of 4798 cases of breast cancer were retrospectively analyzed from the database of the Oncology Center, Mansoura University (OCMU), between January 2008 and December 2019.

Results: Radiologic involvement of multiple quadrants was reported in 27.9% by ultrasonography, 19% by mammography, and 59.1% by magnetic resonance imaging. BCS was performed in 32 cases (6.9%) while 432 cases underwent a mastectomy. Postoperative pathology revealed infiltration of other quadrants grossly in 23.5%, and under the microscope in 63.6% of the examined cases. Mean disease-free and overall survival were 95.5 and 164.6 months, respectively. When compared with MFBC, MCBC showed higher pathologic tumor size (p < 0.001), higher stages (p < 0.001), higher recurrence rates (p = 0.006), and lower DFS (P = 0.009) but with similar OS (P = 0.8).

Conclusion: Mastectomy is still the primary treatment option for MCBC with higher recurrence rates compared with MFBC. However, BCS for properly selected MFBC is considered oncologically safe, following the same rules of breast conservation for unifocal disease.

背景:多灶性(MFBC)/多中心性(MCBC)乳腺癌由于影像学方式的改进和更大的定向,越来越多的人认识到这种形式的乳腺癌,然而,最佳的手术治疗仍然是一个挑战。标准的手术治疗是乳房切除术,然而,在某些情况下,乳房保留手术(BCS)可能是合适的。方法:回顾性分析2008年1月至2019年12月曼苏拉大学肿瘤中心(OCMU)数据库中4798例乳腺癌中464例MF/MCBC。结果:超声检查多象限受累率为27.9%,乳房x光检查为19%,磁共振检查为59.1%。32例(6.9%)行BCS, 432例行乳房切除术。术后病理显示其他象限浸润23.5%,显微镜下浸润63.6%。平均无病生存期和总生存期分别为95.5和164.6个月。与MFBC相比,MCBC显示出更高的病理肿瘤大小(p)结论:乳房切除术仍然是MCBC的主要治疗选择,与MFBC相比,乳腺癌复发率更高。然而,对于适当选择的MFBC, BCS被认为是肿瘤学上安全的,遵循与单一疾病相同的乳房保护规则。
{"title":"The epidemiological and clinicopathological characteristics of multifocal/multicentric breast cancer in the Egyptian Delta and its impact on management strategies.","authors":"Ahmed Abdallah,&nbsp;Omar Hamdy,&nbsp;Mohammad Zuhdy,&nbsp;Saleh S Elbalka,&nbsp;Mohamed Abdelkhalek,&nbsp;Amir M Zaid,&nbsp;Ahmed Atef,&nbsp;Mohamed G Elmadawy,&nbsp;Basel Refky,&nbsp;Khaled Abdel Wahab,&nbsp;Dalia Bayoumi,&nbsp;Khadiga M Ali,&nbsp;Islam H Metwally,&nbsp;Mosab Shetiwy","doi":"10.3233/BD-220066","DOIUrl":"https://doi.org/10.3233/BD-220066","url":null,"abstract":"<p><strong>Background: </strong>Multifocal (MFBC)/multicentric (MCBC) breast cancer is being more recognized due to the improved imaging modalities and the greater orientation with this form of breast cancer, however, optimal surgical treatment, still poses a challenge. The standard surgical treatment is mastectomy, however, breast-conserving surgeries (BCS) may be appropriate in certain situations.</p><p><strong>Methods: </strong>A total of 464 cases of MF/MCBC out of 4798 cases of breast cancer were retrospectively analyzed from the database of the Oncology Center, Mansoura University (OCMU), between January 2008 and December 2019.</p><p><strong>Results: </strong>Radiologic involvement of multiple quadrants was reported in 27.9% by ultrasonography, 19% by mammography, and 59.1% by magnetic resonance imaging. BCS was performed in 32 cases (6.9%) while 432 cases underwent a mastectomy. Postoperative pathology revealed infiltration of other quadrants grossly in 23.5%, and under the microscope in 63.6% of the examined cases. Mean disease-free and overall survival were 95.5 and 164.6 months, respectively. When compared with MFBC, MCBC showed higher pathologic tumor size (p < 0.001), higher stages (p < 0.001), higher recurrence rates (p = 0.006), and lower DFS (P = 0.009) but with similar OS (P = 0.8).</p><p><strong>Conclusion: </strong>Mastectomy is still the primary treatment option for MCBC with higher recurrence rates compared with MFBC. However, BCS for properly selected MFBC is considered oncologically safe, following the same rules of breast conservation for unifocal disease.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"101-114"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9311113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is known about patient-centered care application in post-surgical breast cancer patients? 以患者为中心的护理在乳腺癌术后患者中的应用了解多少?
Pub Date : 2023-01-01 DOI: 10.3233/BD-239004
Shafa Nadia, Fridawaty Rivai, Indahwaty Sidin, Syahrir A Pasinringi

Background: Over the past two decades, patient-centered care has become internationally recognized as a dimension of high-quality health care. Recent research has shown that patient-centered care has many benefits, which are broadly categorized as patient experience and clinical and operational benefits.

Objective: The study aimed at analyzing the correlation between the application of patient-centered care (PCC) and length of stay, patient satisfaction, and clinical outcome of post-surgical breast cancer patients.

Methods: The study design was cross-sectional. A sample of 100 patients was determined and selected with the inclusion criteria. Data were collected using measuring tools comprising patient-centered care and patient satisfaction questionnaires as well as medical records to evaluate the length of stay and clinical outcomes. Bivariate analysis was conducted to analyze the correlation between patient-centered-care and length of stay (LOS), patient satisfaction, and the clinical outcomes of inpatients.

Results: A correlation was found between patient-centered care (PCC) application and patient satisfaction (p = 0.005), but no correlation was observed between PCC application and length of stay (LOS) (p = 0.176) as well as clinical outcome (p = 0.128).

Conclusions: The application of patient-centered care can be attributed to patient satisfaction but is not correlated to length of stay and clinical outcome of post-surgical breast cancer patients. The hospital should create an accepted definition and commonly agreed set of dimensions used for the concept of operationalization and its measurement to implement PCC and improve overall patient satisfaction and clinical outcome and reduce the length of stay as expected.

背景:在过去的二十年中,以患者为中心的护理已成为国际公认的高质量卫生保健的一个方面。最近的研究表明,以患者为中心的护理有很多好处,大致分为患者体验和临床和手术方面的好处。目的:分析以患者为中心的护理(PCC)的应用与乳腺癌术后患者住院时间、患者满意度及临床结局的相关性。方法:采用横断面设计。根据纳入标准确定并选择100例患者。使用测量工具收集数据,包括以患者为中心的护理和患者满意度问卷以及医疗记录,以评估住院时间和临床结果。采用双变量分析分析以患者为中心的护理与住院时间(LOS)、患者满意度和住院患者临床结局的相关性。结果:以患者为中心的护理(PCC)的应用与患者满意度有相关性(p = 0.005),但PCC的应用与住院时间(p = 0.176)和临床结果无相关性(p = 0.128)。结论:以患者为中心的护理的应用可归因于患者满意度,但与乳腺癌术后患者的住院时间和临床结果无关。医院应该创建一个可接受的定义和一组普遍同意的维度,用于操作化的概念及其测量,以实施PCC,提高总体患者满意度和临床结果,并按预期缩短住院时间。
{"title":"What is known about patient-centered care application in post-surgical breast cancer patients?","authors":"Shafa Nadia,&nbsp;Fridawaty Rivai,&nbsp;Indahwaty Sidin,&nbsp;Syahrir A Pasinringi","doi":"10.3233/BD-239004","DOIUrl":"https://doi.org/10.3233/BD-239004","url":null,"abstract":"<p><strong>Background: </strong>Over the past two decades, patient-centered care has become internationally recognized as a dimension of high-quality health care. Recent research has shown that patient-centered care has many benefits, which are broadly categorized as patient experience and clinical and operational benefits.</p><p><strong>Objective: </strong>The study aimed at analyzing the correlation between the application of patient-centered care (PCC) and length of stay, patient satisfaction, and clinical outcome of post-surgical breast cancer patients.</p><p><strong>Methods: </strong>The study design was cross-sectional. A sample of 100 patients was determined and selected with the inclusion criteria. Data were collected using measuring tools comprising patient-centered care and patient satisfaction questionnaires as well as medical records to evaluate the length of stay and clinical outcomes. Bivariate analysis was conducted to analyze the correlation between patient-centered-care and length of stay (LOS), patient satisfaction, and the clinical outcomes of inpatients.</p><p><strong>Results: </strong>A correlation was found between patient-centered care (PCC) application and patient satisfaction (p = 0.005), but no correlation was observed between PCC application and length of stay (LOS) (p = 0.176) as well as clinical outcome (p = 0.128).</p><p><strong>Conclusions: </strong>The application of patient-centered care can be attributed to patient satisfaction but is not correlated to length of stay and clinical outcome of post-surgical breast cancer patients. The hospital should create an accepted definition and commonly agreed set of dimensions used for the concept of operationalization and its measurement to implement PCC and improve overall patient satisfaction and clinical outcome and reduce the length of stay as expected.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"233-243"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9952373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Reference to "Rural Otolaryngology Care Disparities: A Scoping Review". 关于 "农村耳鼻喉科护理差异:范围审查"。
IF 2.6 Pub Date : 2022-06-01 DOI: 10.1177/01945998221083834
Andrew Morel, Jason E Cohn
{"title":"In Reference to \"Rural Otolaryngology Care Disparities: A Scoping Review\".","authors":"Andrew Morel, Jason E Cohn","doi":"10.1177/01945998221083834","DOIUrl":"10.1177/01945998221083834","url":null,"abstract":"","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1 1","pages":"1228"},"PeriodicalIF":2.6,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89411165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determinants of mammography screening in Iranian women: A systematic review and meta-analysis. 伊朗妇女乳腺钼靶筛查的决定因素:一项系统综述和荟萃分析。
Pub Date : 2022-05-26 DOI: 10.3233/bd-210037
Khadijeh Kalan Farmanfarma, N. Mahdavifar, Somayeh Heidarpour Kiasara, Soheil Hassanipour, H. Salehiniya
BACKGROUNDMammography is the most effective method for early detection of breast cancer (BC), however, it has performed in low-level. The aim of this study was to investigate the determinants of mammography in Iran.METHODSThis study was a systematic review which was performed based on articles published in both Persian and English languages among Iranian patients in the period of 2000 to 2020 by using keywords of "Iran and mammography". Papers were selected from national databases including (SID, Magiran) and international database including (Scopus, PubMed and web of science), finally related articles to mammography were reviewed.RESULTSFindings indicated that 35-50% of breast cancer can be detected in the early stages by mammography, however, it is in low rate of performance among Iranian women. Age, age of menarche, occupation, family history, marital status, family support, number of pregnancies, physician recommendations, perceived sensibility and severity, self-efficacy and perceived benefits are the most important predictors of performing mammography in Iran.CONCLUSIONDue to the growing trend of breast cancer cases in the country and low mammography rates in Iranian population, high risk groups such as women with BC family history, low income level, low education level, older age and people with history of breast complications were more emphasized for performing mammography through health centers. Therefore, appropriate planning to reduce the barriers of mammography could be helpful.
背景:乳房x光检查是早期发现乳腺癌(BC)最有效的方法,然而,它在低水平上表现不佳。本研究的目的是调查伊朗乳房x光检查的决定因素。方法以“伊朗与乳房x线摄影”为关键词,对2000 ~ 2020年伊朗患者发表的波斯语和英语文献进行系统综述。论文从国内数据库(SID、Magiran)和国际数据库(Scopus、PubMed、web of science)中选取,最后对乳房x线摄影相关文章进行综述。结果研究结果表明,35-50%的乳腺癌可以通过乳房x光检查在早期发现,然而,在伊朗妇女中,这一比例很低。年龄、月经初潮年龄、职业、家族史、婚姻状况、家庭支持、怀孕次数、医生建议、感知敏感性和严重程度、自我效能和感知益处是在伊朗进行乳房x光检查的最重要预测因素。结论由于伊朗国内乳腺癌病例呈上升趋势,而伊朗人群的乳腺x光检查率较低,有BC家族史、收入水平低、受教育程度低、年龄较大、有乳腺并发症史的高危人群更应通过保健中心进行乳腺x光检查。因此,适当的计划减少乳房x光检查的障碍可能是有帮助的。
{"title":"Determinants of mammography screening in Iranian women: A systematic review and meta-analysis.","authors":"Khadijeh Kalan Farmanfarma, N. Mahdavifar, Somayeh Heidarpour Kiasara, Soheil Hassanipour, H. Salehiniya","doi":"10.3233/bd-210037","DOIUrl":"https://doi.org/10.3233/bd-210037","url":null,"abstract":"BACKGROUND\u0000Mammography is the most effective method for early detection of breast cancer (BC), however, it has performed in low-level. The aim of this study was to investigate the determinants of mammography in Iran.\u0000\u0000\u0000METHODS\u0000This study was a systematic review which was performed based on articles published in both Persian and English languages among Iranian patients in the period of 2000 to 2020 by using keywords of \"Iran and mammography\". Papers were selected from national databases including (SID, Magiran) and international database including (Scopus, PubMed and web of science), finally related articles to mammography were reviewed.\u0000\u0000\u0000RESULTS\u0000Findings indicated that 35-50% of breast cancer can be detected in the early stages by mammography, however, it is in low rate of performance among Iranian women. Age, age of menarche, occupation, family history, marital status, family support, number of pregnancies, physician recommendations, perceived sensibility and severity, self-efficacy and perceived benefits are the most important predictors of performing mammography in Iran.\u0000\u0000\u0000CONCLUSION\u0000Due to the growing trend of breast cancer cases in the country and low mammography rates in Iranian population, high risk groups such as women with BC family history, low income level, low education level, older age and people with history of breast complications were more emphasized for performing mammography through health centers. Therefore, appropriate planning to reduce the barriers of mammography could be helpful.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"41 1 1","pages":"279-294"},"PeriodicalIF":0.0,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42578561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Accelerated radiotherapy in patients over sixty years old after mastectomy: Acute and one-year physician-assessed toxicity and health-related quality of life. 60岁以上乳房切除术后患者的加速放疗:急性和一年医生评估的毒性和健康相关的生活质量
Pub Date : 2022-05-20 DOI: 10.3233/bd-210080
Vincent Vakaet, Hans Van Hulle, Viktor Quataert, P. Deseyne, Max Schoepen, L. Paelinck, G. Post, A. V. Van Greveling, B. Speleers, M. Mareel, W. De Neve, C. Monten, L. Veldeman
INTRODUCTIONPostmastectomy radiotherapy reduces the risk of locoregional recurrence in breast cancer patients. The first results on accelerated radiotherapy in five fractions after breast conserving surgery are promising. The data on postmastectomy radiotherapy in five or six fractions is limited. We now present the data on acute and one-year toxicity and health related quality of life (HRQoL) after postmastectomy radiotherapy in patients of sixty years or older.METHODOLOGY119 patients received five fractions of 5.7 Gy to the chest wall and five fractions of 5.4 Gy to the lymph nodes over ten to twelve days. Physician-assessed toxicity were scored using the Common Terminology Criteria for Adverse Events version 4.03 toxicity scoring system and the LENT-SOMA scale. Fatigue was measured by the Multidimensional Fatigue Inventory (MFI-206). HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire the breast cancer specific module and the BREAST-Q questionnaire.RESULTSFatigue and edema were the most frequently observed physician-assessed toxicities. One year after radiotherapy only 12.9% experienced a clinically important deterioration in chest wall symptoms and in 22.9% of the patients were improved. Future perspective at one year after radiotherapy was improved in 40.0% of the patients. Patient-reported fatigue showed the greatest improvement.CONCLUSIONAccelerated radiotherapy should be considered to minimize the burden of breast cancer treatment, especially in older patients.
简介术后放疗可降低癌症患者局部复发的风险。保乳手术后加速放疗五个部分的第一个结果是有希望的。骨切除术后放疗的五个或六个部分的数据是有限的。我们现在提供了60岁或以上患者切除骨后放疗后急性和一年毒性及健康相关生活质量(HRQoL)的数据。方法119名患者在10至12天内接受5次5.7 Gy的胸壁照射和5次5.4 Gy的淋巴结照射。医生评估的毒性使用不良事件通用术语标准4.03版毒性评分系统和LENT-SOMA量表进行评分。疲劳通过多维疲劳量表(MFI-206)进行测量。使用欧洲癌症研究与治疗组织生活质量问卷、癌症特异性模块和BREST-Q问卷对HRQoL进行评估。结果疲劳和水肿是医生评估的最常见的毒性。放疗一年后,只有12.9%的患者胸壁症状出现临床重要恶化,22.9%的患者病情有所好转。40.0%的患者在放疗后一年的未来前景得到改善。患者报告的疲劳表现出最大的改善。结论应考虑加速放疗,以尽量减轻癌症治疗的负担,尤其是老年患者。
{"title":"Accelerated radiotherapy in patients over sixty years old after mastectomy: Acute and one-year physician-assessed toxicity and health-related quality of life.","authors":"Vincent Vakaet, Hans Van Hulle, Viktor Quataert, P. Deseyne, Max Schoepen, L. Paelinck, G. Post, A. V. Van Greveling, B. Speleers, M. Mareel, W. De Neve, C. Monten, L. Veldeman","doi":"10.3233/bd-210080","DOIUrl":"https://doi.org/10.3233/bd-210080","url":null,"abstract":"INTRODUCTION\u0000Postmastectomy radiotherapy reduces the risk of locoregional recurrence in breast cancer patients. The first results on accelerated radiotherapy in five fractions after breast conserving surgery are promising. The data on postmastectomy radiotherapy in five or six fractions is limited. We now present the data on acute and one-year toxicity and health related quality of life (HRQoL) after postmastectomy radiotherapy in patients of sixty years or older.\u0000\u0000\u0000METHODOLOGY\u0000119 patients received five fractions of 5.7 Gy to the chest wall and five fractions of 5.4 Gy to the lymph nodes over ten to twelve days. Physician-assessed toxicity were scored using the Common Terminology Criteria for Adverse Events version 4.03 toxicity scoring system and the LENT-SOMA scale. Fatigue was measured by the Multidimensional Fatigue Inventory (MFI-206). HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire the breast cancer specific module and the BREAST-Q questionnaire.\u0000\u0000\u0000RESULTS\u0000Fatigue and edema were the most frequently observed physician-assessed toxicities. One year after radiotherapy only 12.9% experienced a clinically important deterioration in chest wall symptoms and in 22.9% of the patients were improved. Future perspective at one year after radiotherapy was improved in 40.0% of the patients. Patient-reported fatigue showed the greatest improvement.\u0000\u0000\u0000CONCLUSION\u0000Accelerated radiotherapy should be considered to minimize the burden of breast cancer treatment, especially in older patients.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"41 1 1","pages":"261-266"},"PeriodicalIF":0.0,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44868896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report. 炎症性乳腺癌对派姆单抗联合化疗的良好反应:1例报告。
Pub Date : 2022-05-17 DOI: 10.3233/bd-210041
Zeni Kharel, Omar P Nemer, Wang Xi, Bimala Upadhayaya, C. Falkson, Ruth M O'Regan, Ajay Dhakal
Inflammatory breast cancer (IBC) is a rare variety of breast cancer accounting for two percent of breast cancer diagnoses in the United States. It is characterized by peau d'orange, breast edema and erythema on physical examination and dermal lymphatic invasion by tumor emboli on histological examination. Micrometastases to lymphatics and bone marrow at the time of diagnosis and angiogenic properties of IBC explain the high propensity of this cancer to relapse and metastasize, its aggressiveness and poor prognosis. Preoperative sequential anthracycline and taxane (plus trastuzumab and pertuzumab if HER2-positive) based chemotherapy is the current standard of care for IBC. We herein report a case of stage IIIC triple-negative IBC treated with pembrolizumab plus chemotherapy based neoadjuvant therapy with a complete clinical and complete pathological response. This is the first case of triple-negative IBC treated with this regimen reported in the literature, thereby providing clinical data on the tolerability and efficacy of pembrolizumab plus chemotherapy based neoadjuvant regimen for the treatment of IBC.
炎症性乳腺癌(IBC)是一种罕见的乳腺癌,占美国乳腺癌诊断的2%。其特征为体格检查表现为橙色点,乳房水肿和红斑,组织学检查表现为肿瘤栓塞侵犯真皮淋巴。诊断时淋巴和骨髓的微转移和IBC的血管生成特性解释了这种癌症复发和转移的高倾向,其侵袭性和预后差。术前序贯蒽环类药物和紫杉烷(如果her2阳性,则加曲妥珠单抗和帕妥珠单抗)化疗是目前IBC的标准治疗方案。我们在此报告一例IIIC期三阴性IBC患者,采用派姆单抗加化疗为基础的新辅助治疗,具有完全的临床和病理反应。这是文献中报道的第一例使用该方案治疗三阴性IBC的病例,从而提供了派姆单抗加化疗新辅助方案治疗IBC的耐受性和有效性的临床数据。
{"title":"Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.","authors":"Zeni Kharel, Omar P Nemer, Wang Xi, Bimala Upadhayaya, C. Falkson, Ruth M O'Regan, Ajay Dhakal","doi":"10.3233/bd-210041","DOIUrl":"https://doi.org/10.3233/bd-210041","url":null,"abstract":"Inflammatory breast cancer (IBC) is a rare variety of breast cancer accounting for two percent of breast cancer diagnoses in the United States. It is characterized by peau d'orange, breast edema and erythema on physical examination and dermal lymphatic invasion by tumor emboli on histological examination. Micrometastases to lymphatics and bone marrow at the time of diagnosis and angiogenic properties of IBC explain the high propensity of this cancer to relapse and metastasize, its aggressiveness and poor prognosis. Preoperative sequential anthracycline and taxane (plus trastuzumab and pertuzumab if HER2-positive) based chemotherapy is the current standard of care for IBC. We herein report a case of stage IIIC triple-negative IBC treated with pembrolizumab plus chemotherapy based neoadjuvant therapy with a complete clinical and complete pathological response. This is the first case of triple-negative IBC treated with this regimen reported in the literature, thereby providing clinical data on the tolerability and efficacy of pembrolizumab plus chemotherapy based neoadjuvant regimen for the treatment of IBC.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"41 1 1","pages":"255-260"},"PeriodicalIF":0.0,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45132645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines. PIK3CA/mTOR抑制在三阴性乳腺癌症亚型细胞系中的体外作用。
Pub Date : 2022-04-11 DOI: 10.3233/bd-210066
S. Kumar, S. Bhattacharyya, A. Das, Gurpreet Singh, A. Bal
BACKGROUNDAgents targeting the PI3K pathway in triple negative breast cancer did not show any significant efficacy so far mostly because of the complex nature of these targeted inhibitors. Targeting the cancer cells with the combination of inhibitors may help in decelerating the regulatory pathways further achieving optimum clinical benefit. In this study, we investigated the effect of PIK3CA and mTOR inhibition in-vitro in triple-negative breast cancer (TNBC) cell lines.OBJECTIVE AND METHODSThree TNBC cell lines; MDA MB231, MDA MB468, and MDA MB453 were subtyped using immunohistochemistry and were screened for hotspot mutations in PIK3CA and AKT1. All cell lines were treated with different concentrations of inhibitors; PI3K inhibitor (BKM 120), mTOR inhibitor (AZD 8055), and dual PI3K/mTOR inhibitor (BEZ 235), and cell viability was assessed by MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide), Trypan blue and Annexin-V/PI Assays.RESULTSUsing immunohistochemistry, TNBC cell lines were subtyped as; mesenchymal subtype-specific cell line (MDA MB231), basal subtype-specific cell line (MDA MD468), and Luminal androgen receptor (LAR) subtype-specific cell line (MDA MB453). PIK3CA hot spot mutation (p.H1047R) in exon 20 was identified in the Luminal androgen receptor subtype (MDA MB453 cells) cell line. Cell viability assays showed that the Mesenchymal subtype-specific cell line (MDA MB231) was the most resistant to all inhibitors and the Luminal Androgen subtype (MDA MB453 cells) cell line was more sensitive to BKM120 (PI3K inhibitor) inhibition compared to other subtypes.CONCLUSIONSThis study identified that the Luminal androgen receptor subtype of triple-negative breast cancer with PIK3CA mutation may be targeted with PIK3CA inhibitors with a favorable outcome.
背景在癌症三阴性中靶向PI3K途径的药物到目前为止没有显示出任何显著的疗效,主要是因为这些靶向抑制剂的复杂性。用抑制剂组合靶向癌症细胞可能有助于减缓调节途径,进一步实现最佳临床效益。在本研究中,我们研究了PIK3CA和mTOR在体外对癌症(TNBC)三阴性细胞系的抑制作用。目的和方法建立三种TNBC细胞系;使用免疫组织化学对MDA MB231、MDA MB468和MDA MB453进行分型,并筛选PIK3CA和AKT1中的热点突变。用不同浓度的抑制剂处理所有细胞系;PI3K抑制剂(BKM 120)、mTOR抑制剂(AZD 8055)和双PI3K/mTOR抑制剂(BEZ 235),并通过MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化物)、台盼蓝和Annexin-V/PI分析评估细胞活力;间充质亚型特异性细胞系(MDA MB231)、基础亚型特性细胞系(MDA-MD468)和灯具雄激素受体(LAR)亚型特异地细胞系(丙二醛MB453)。在Luminal雄激素受体亚型(MDA MB453细胞)细胞系中鉴定出外显子20中的PIK3CA热点突变(p.H1047R)。细胞活力测定显示,与其他亚型相比,间充质亚型特异性细胞系(MDA MB231)对所有抑制剂最具耐药性,而Luminal Androgen亚型(MDA MB453细胞)对BKM120(PI3K抑制剂)抑制更敏感。结论本研究发现,PIK3CA突变的癌症三阴性Luminal雄激素受体亚型可能是PIK3CA抑制剂的靶向物,结果良好。
{"title":"In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.","authors":"S. Kumar, S. Bhattacharyya, A. Das, Gurpreet Singh, A. Bal","doi":"10.3233/bd-210066","DOIUrl":"https://doi.org/10.3233/bd-210066","url":null,"abstract":"BACKGROUND\u0000Agents targeting the PI3K pathway in triple negative breast cancer did not show any significant efficacy so far mostly because of the complex nature of these targeted inhibitors. Targeting the cancer cells with the combination of inhibitors may help in decelerating the regulatory pathways further achieving optimum clinical benefit. In this study, we investigated the effect of PIK3CA and mTOR inhibition in-vitro in triple-negative breast cancer (TNBC) cell lines.\u0000\u0000\u0000OBJECTIVE AND METHODS\u0000Three TNBC cell lines; MDA MB231, MDA MB468, and MDA MB453 were subtyped using immunohistochemistry and were screened for hotspot mutations in PIK3CA and AKT1. All cell lines were treated with different concentrations of inhibitors; PI3K inhibitor (BKM 120), mTOR inhibitor (AZD 8055), and dual PI3K/mTOR inhibitor (BEZ 235), and cell viability was assessed by MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide), Trypan blue and Annexin-V/PI Assays.\u0000\u0000\u0000RESULTS\u0000Using immunohistochemistry, TNBC cell lines were subtyped as; mesenchymal subtype-specific cell line (MDA MB231), basal subtype-specific cell line (MDA MD468), and Luminal androgen receptor (LAR) subtype-specific cell line (MDA MB453). PIK3CA hot spot mutation (p.H1047R) in exon 20 was identified in the Luminal androgen receptor subtype (MDA MB453 cells) cell line. Cell viability assays showed that the Mesenchymal subtype-specific cell line (MDA MB231) was the most resistant to all inhibitors and the Luminal Androgen subtype (MDA MB453 cells) cell line was more sensitive to BKM120 (PI3K inhibitor) inhibition compared to other subtypes.\u0000\u0000\u0000CONCLUSIONS\u0000This study identified that the Luminal androgen receptor subtype of triple-negative breast cancer with PIK3CA mutation may be targeted with PIK3CA inhibitors with a favorable outcome.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"41 1 1","pages":"241-247"},"PeriodicalIF":0.0,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46400007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The association of human cytomegalovirus with biomarkers of inflammation and immune activation in breast cancer. 人类巨细胞病毒与癌症炎症和免疫激活生物标志物的相关性。
Pub Date : 2022-04-05 DOI: 10.3233/bd-210060
S. Youssry, A. Hussein, R. Ramadan, Ahmad Alkarmouty, Amel Elsheredy
BACKGROUNDThe presence of human cytomegalovirus (HCMV) in breast cancer has been reported, suggesting a potential association between HCMV infection and breast carcinogenesis.OBJECTIVETo evaluate the association between HCMV infection and immune activation and inflammatory markers in breast cancer.METHODSHCMV DNA was detected from all patients using real-time PCR, Anti HCMV IgM and IgG antibodies were measured. IL-17 and IL-22 concentrations were detected by ELISA. Assessment of NLR and PLR was done, and cell proliferation was assessed using MTT assay.RESULTSThe results revealed a significantly increased prevalence of anti-HCMV IgG and HCMV DNA in patients compared to both benign and control groups where positive HCMV prevalence was significantly associated with vascular invasion, proliferation rate, high neutrophil-to-lymphocyte ratio (NLR), and elevated IL-17 serum level. Furthermore, we demonstrated that increased serum IL-17 in patients was markedly associated with tumor stage, vascular invasion, and high NLR.CONCLUSIONIt can be concluded that HCMV infection may have vital roles in breast cancer pathogenesis. Moreover, altered peripheral blood cells and cytokines may result in disordered immune response in breast cancer patients.
背景人类巨细胞病毒(HCMV)在乳腺癌中的存在已被报道,提示HCMV感染与乳腺癌发生之间可能存在关联。目的探讨乳腺癌患者HCMV感染与免疫激活及炎症标志物的关系。方法采用实时荧光定量PCR检测所有患者的HCMV DNA,检测抗HCMV IgM和IgG抗体。ELISA法检测各组IL-17、IL-22浓度。检测NLR和PLR, MTT法检测细胞增殖。结果结果显示,与良性组和对照组相比,患者中抗HCMV IgG和HCMV DNA的患病率显著增加,而良性组和对照组的HCMV阳性患病率与血管侵入、增殖率、高中性粒细胞与淋巴细胞比率(NLR)和血清IL-17水平升高显著相关。此外,我们证明了患者血清IL-17的增加与肿瘤分期、血管浸润和高NLR显著相关。结论HCMV感染可能在乳腺癌发病过程中起重要作用。此外,外周血细胞和细胞因子的改变可能导致乳腺癌患者免疫反应紊乱。
{"title":"The association of human cytomegalovirus with biomarkers of inflammation and immune activation in breast cancer.","authors":"S. Youssry, A. Hussein, R. Ramadan, Ahmad Alkarmouty, Amel Elsheredy","doi":"10.3233/bd-210060","DOIUrl":"https://doi.org/10.3233/bd-210060","url":null,"abstract":"BACKGROUND\u0000The presence of human cytomegalovirus (HCMV) in breast cancer has been reported, suggesting a potential association between HCMV infection and breast carcinogenesis.\u0000\u0000\u0000OBJECTIVE\u0000To evaluate the association between HCMV infection and immune activation and inflammatory markers in breast cancer.\u0000\u0000\u0000METHODS\u0000HCMV DNA was detected from all patients using real-time PCR, Anti HCMV IgM and IgG antibodies were measured. IL-17 and IL-22 concentrations were detected by ELISA. Assessment of NLR and PLR was done, and cell proliferation was assessed using MTT assay.\u0000\u0000\u0000RESULTS\u0000The results revealed a significantly increased prevalence of anti-HCMV IgG and HCMV DNA in patients compared to both benign and control groups where positive HCMV prevalence was significantly associated with vascular invasion, proliferation rate, high neutrophil-to-lymphocyte ratio (NLR), and elevated IL-17 serum level. Furthermore, we demonstrated that increased serum IL-17 in patients was markedly associated with tumor stage, vascular invasion, and high NLR.\u0000\u0000\u0000CONCLUSION\u0000It can be concluded that HCMV infection may have vital roles in breast cancer pathogenesis. Moreover, altered peripheral blood cells and cytokines may result in disordered immune response in breast cancer patients.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"41 1 1","pages":"229-239"},"PeriodicalIF":0.0,"publicationDate":"2022-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45098663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An integrative ultrasound-pathology approach to improve preoperative phyllodes tumor classification: A pilot study. 综合超声病理方法改善术前叶状肿瘤分类:一项初步研究。
Pub Date : 2022-04-04 DOI: 10.3233/bd-210025
Paola Locicero, N. Weingertner, V. Noblet, M. Mondino, C. Mathelin, S. Molière
OBJECTIVEPreoperative diagnosis of phyllodes tumor (PT) is challenging, core-needle biopsy (CNB) has a significant rate of understaging, resulting in suboptimal surgical planification. We hypothesized that the association of imaging data to CNB would improve preoperative diagnostic accuracy compared to biopsy alone.METHODSIn this retrospective pilot study, we included 59 phyllodes tumor with available preoperative imaging, CNB and surgical specimen pathology.RESULTSTwo ultrasound features: tumor heterogeneity and tumor shape were associated with tumor grade, independently of CNB results. Using a machine learning classifier, the association of ultrasound features with CNB results improved accuracy of preoperative tumor classification up to 84%.CONCLUSIONAn integrative approach of preoperative diagnosis, associating ultrasound features and CNB, improves preoperative diagnosis and could thus optimize surgical planification.
目的:叶状瘤(PT)的术前诊断具有挑战性,核心针活检(CNB)有明显的分期不足率,导致手术平整度不理想。我们假设,与单独活检相比,影像数据与CNB的关联可以提高术前诊断的准确性。方法回顾性初步研究纳入59例有术前影像学、超声心动图和手术标本病理资料的分叶状肿瘤。结果两项超声特征:肿瘤异质性和肿瘤形态与肿瘤分级相关,与CNB结果无关。使用机器学习分类器,超声特征与CNB结果的关联将术前肿瘤分类的准确率提高了84%。结论术前综合诊断,将超声特征与CNB相结合,可提高术前诊断水平,优化手术平面化。
{"title":"An integrative ultrasound-pathology approach to improve preoperative phyllodes tumor classification: A pilot study.","authors":"Paola Locicero, N. Weingertner, V. Noblet, M. Mondino, C. Mathelin, S. Molière","doi":"10.3233/bd-210025","DOIUrl":"https://doi.org/10.3233/bd-210025","url":null,"abstract":"OBJECTIVE\u0000Preoperative diagnosis of phyllodes tumor (PT) is challenging, core-needle biopsy (CNB) has a significant rate of understaging, resulting in suboptimal surgical planification. We hypothesized that the association of imaging data to CNB would improve preoperative diagnostic accuracy compared to biopsy alone.\u0000\u0000\u0000METHODS\u0000In this retrospective pilot study, we included 59 phyllodes tumor with available preoperative imaging, CNB and surgical specimen pathology.\u0000\u0000\u0000RESULTS\u0000Two ultrasound features: tumor heterogeneity and tumor shape were associated with tumor grade, independently of CNB results. Using a machine learning classifier, the association of ultrasound features with CNB results improved accuracy of preoperative tumor classification up to 84%.\u0000\u0000\u0000CONCLUSION\u0000An integrative approach of preoperative diagnosis, associating ultrasound features and CNB, improves preoperative diagnosis and could thus optimize surgical planification.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"41 1 1","pages":"221-228"},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46472176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1